(HealthDay News) — HIV-positive donor to HIV-positive recipient (HIV D+/R+) kidney transplantation (KT) is feasible, according to a study published online in the American Journal of Transplantation.
Christine M. Durand, MD, from the Johns Hopkins University School of Medicine in Baltimore, and colleagues explored safety and risk attributable to an HIV+ donor. HIV D+/R+ KT was compared to HIV-negative donor to HIV+ recipient (HIV D−/R+) KT. Data were included for 75 HIV+ KTs, including 25 D+ and 50 D−, followed for a median of 1.7 years.
The researchers found no deaths were reported and there were no differences in D+ versus D− in one-year graft survival (91 vs 92%), 1-year mean estimated glomerular filtration rate (63 vs 57 mL/min), HIV breakthrough (4 vs 6%), infectious hospitalizations (28 vs 26%), or opportunistic infections (16 vs 12%). D+ recipients had higher 1-year rejection, although the difference was not statistically significant (50 vs 29%; hazard ratio, 1.83; 95% confidence interval, 0.84 to 3.95; P=0.13); lower rejection was seen with lymphocyte-depleting induction (21 vs 44%; hazard ratio, 0.33; 95% confidence interval, 0.21 to 0.87; P=0.03).
“This unique donor organ source has the potential to mitigate disparities for a vulnerable population that faces lower access to transplant and higher waitlist mortality,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.